Neurocrine Biosciences (NBIX) Projected to Release Earnings on Thursday

Neurocrine Biosciences (NASDAQ:NBIX) is expected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Neurocrine Biosciences to announce earnings of $1.62 per share and revenue of $890.8630 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $172.69 on Thursday. The company has a 50 day simple moving average of $164.88 and a two-hundred day simple moving average of $144.50. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $181.18. The company has a market capitalization of $17.36 billion, a price-to-earnings ratio of 26.61, a P/E/G ratio of 0.71 and a beta of 0.39.

Insider Transactions at Neurocrine Biosciences

In other news, Director Stephen A. Sherwin sold 25,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the sale, the director owned 15,860 shares in the company, valued at $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the sale, the director directly owned 511,293 shares of the company’s stock, valued at $78,907,848.69. This trade represents a 32.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 394,172 shares of company stock valued at $62,221,181. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of NBIX. Geneos Wealth Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. Meeder Asset Management Inc. boosted its position in shares of Neurocrine Biosciences by 651.6% during the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after buying an additional 202 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Neurocrine Biosciences in the 4th quarter worth about $39,000. Kestra Advisory Services LLC bought a new stake in Neurocrine Biosciences in the 4th quarter worth about $53,000. Finally, Aster Capital Management DIFC Ltd increased its holdings in Neurocrine Biosciences by 74.4% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 614 shares of the company’s stock worth $87,000 after buying an additional 262 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on NBIX shares. Guggenheim upped their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $185.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 6th. Canaccord Genuity Group boosted their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Citigroup boosted their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $194.05.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.